Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population.

Bogart M, Stanford RH, Laliberté F, Germain G, Wu JW, Duh MS.

Int J Chron Obstruct Pulmon Dis. 2019 Feb 19;14:343-352. doi: 10.2147/COPD.S184653. eCollection 2019.

2.

Duration of anticoagulant therapy and VTE recurrence in patients with cancer.

Khorana AA, McCrae KR, Milentijevic D, Fortier J, Nelson WW, Laliberté F, Crivera C, Lefebvre P, Schein J.

Support Care Cancer. 2019 Feb 8. doi: 10.1007/s00520-019-4661-3. [Epub ahead of print]

PMID:
30734088
3.

Ejection fraction, B-type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure.

Greenberg B, Peterson ED, Berger JS, Laliberté F, Zhao Q, Germain G, Lejeune D, Wu JW, Lefebvre P, Fonarow GC.

Clin Cardiol. 2019 Feb;42(2):277-284. doi: 10.1002/clc.23140. Epub 2019 Jan 7.

4.

Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis).

Korjian S, Daaboul Y, Laliberté F, Zhao Q, Mehran R, Bode C, Halperin J, Verheugt FWA, Lip GYH, Cohen M, Peterson ED, Fox KAA, Gibson CM, Pinto DS; PIONEER AF-PCI Investigators.

Am J Cardiol. 2019 Feb 1;123(3):355-360. doi: 10.1016/j.amjcard.2018.10.033. Epub 2018 Nov 6.

PMID:
30502047
5.

The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation.

Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberté F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff MB.

Am J Hematol. 2019 Feb;94(2):E58-E61. doi: 10.1002/ajh.25361. Epub 2018 Dec 18. No abstract available.

PMID:
30474161
6.

Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.

Laliberté F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

Menopause. 2018 Nov;25(11):1297-1305. doi: 10.1097/GME.0000000000001232.

PMID:
30358726
7.

Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study.

Tarhini A, Ghate S, Ionescu-Ittu R, Shi S, Nakasato A, Ndife B, Laliberté F, Burne R, Duh MS.

Future Oncol. 2019 Feb;15(4):359-370. doi: 10.2217/fon-2018-0671. Epub 2018 Oct 15.

PMID:
30317881
8.

Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients.

McHorney CA, Peterson ED, Ashton V, Laliberté F, Crivera C, Germain G, Sheikh N, Schein J, Lefebvre P.

Curr Med Res Opin. 2018 Oct 30:1-8. doi: 10.1080/03007995.2018.1530205. [Epub ahead of print]

PMID:
30265159
9.

Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.

Ghate S, Ionescu-Ittu R, Burne R, Ndife B, Laliberté F, Nakasato A, Duh MS.

Melanoma Res. 2018 Oct 9. doi: 10.1097/CMR.0000000000000504. [Epub ahead of print]

PMID:
30247203
10.

Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma.

Tarhini A, Ghate SR, Ionescu-Ittu R, Manceur AM, Ndife B, Jacques P, Laliberté F, Nakasato A, Burne R, Duh MS.

Melanoma Res. 2018 Dec;28(6):618-628. doi: 10.1097/CMR.0000000000000507.

11.

Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population.

Wells PS, Prins MH, Beyer-Westendorf J, Lensing AWA, Haskell L, Levitan B, Laliberté F, Ashton V, Xiao Y, Lejeune D, Crivera C, Lefebvre P, Zhao Q, Yuan Z, Schein J, Prandoni P.

Chest. 2018 Dec;154(6):1371-1378. doi: 10.1016/j.chest.2018.08.1059. Epub 2018 Sep 7.

12.

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism.

Berger JS, Seheult R, Laliberté F, Crivera C, Lejeune D, Xiao Y, Schein J, Lefebvre P, Kaatz S.

Res Pract Thromb Haemost. 2017 Nov 15;2(1):58-68. doi: 10.1002/rth2.12050. eCollection 2018 Jan.

13.

Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy.

Ghate SR, Ionescu-Ittu R, Burne R, Ndife B, Laliberté F, Nakasato A, Duh MS.

Curr Med Res Opin. 2018 Dec;34(12):2169-2176. doi: 10.1080/03007995.2018.1501351. Epub 2018 Aug 5.

PMID:
30009647
14.

An answer to "anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution".

Streiff MB, Milentijevic D, McCrae K, Yannicelli D, Lejeune D, Nelson WW, Laliberté F, Crivera C, Lefebvre P, Schein J, Khorana AA.

Am J Hematol. 2018 Sep;93(9):E225-E227. doi: 10.1002/ajh.25165. Epub 2018 Aug 7. No abstract available.

PMID:
29905381
15.

CMS hospital readmission reduction program and anticoagulants received following a total hip and knee arthroplasty discharge.

Laliberté F, Coleman CI, Bookhart B, Schein J, Martin S, Wynant W, Xiao Y, Lefebvre P, Kaatz S.

Curr Med Res Opin. 2018 Nov;34(11):1967-1974. doi: 10.1080/03007995.2018.1475347. Epub 2018 Jun 12.

PMID:
29749269
16.

Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users.

McHorney CA, Crivera C, Laliberté F, Germain G, Wynant W, Lefebvre P.

PLoS One. 2018 Apr 5;13(4):e0194099. doi: 10.1371/journal.pone.0194099. eCollection 2018.

17.

Risk of Ischemic Stroke in Patients Newly Diagnosed With Heart Failure: Focus on Patients Without Atrial Fibrillation.

Berger JS, Peterson E, Laliberté F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir MR.

J Card Fail. 2018 Mar 27. pii: S1071-9164(18)30129-5. doi: 10.1016/j.cardfail.2018.03.012. [Epub ahead of print]

18.

Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results.

Wells PS, Lensing AWA, Haskell L, Levitan B, Laliberté F, Durkin M, Ashton V, Xiao Y, Crivera C, Lejeune D, Schein J, Lefebvre P.

J Med Econ. 2018 Jun;21(6):587-594. doi: 10.1080/13696998.2018.1444615. Epub 2018 Mar 16.

PMID:
29469638
19.

Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.

Streiff MB, Milentijevic D, McCrae K, Yannicelli D, Fortier J, Nelson WW, Laliberté F, Crivera C, Lefebvre P, Schein J, Khorana AA.

Am J Hematol. 2018 May;93(5):664-671. doi: 10.1002/ajh.25059. Epub 2018 Feb 23.

20.

Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function
.

Weir MR, Haskell L, Berger JS, Ashton V, Laliberté F, Crivera C, Brown K, Lefebvre P, Schein J.

Clin Nephrol. 2018 May;89(5):314-329. doi: 10.5414/CN109281.

PMID:
29231162
21.

Pseudogap phase of cuprate superconductors confined by Fermi surface topology.

Doiron-Leyraud N, Cyr-Choinière O, Badoux S, Ataei A, Collignon C, Gourgout A, Dufour-Beauséjour S, Tafti FF, Laliberté F, Boulanger ME, Matusiak M, Graf D, Kim M, Zhou JS, Momono N, Kurosawa T, Takagi H, Taillefer L.

Nat Commun. 2017 Dec 11;8(1):2044. doi: 10.1038/s41467-017-02122-x.

22.

Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation.

Kaatz S, Coleman CI, Bookhart B, Laliberté F, Nelson WW, Brown K, Martin S, Schein J, Lefebvre P.

Curr Med Res Opin. 2018 Feb;34(2):275-284. doi: 10.1080/03007995.2017.1409200. Epub 2017 Dec 22.

PMID:
29164990
23.

Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.

McHorney CA, Ashton V, Laliberté F, Germain G, Wynant W, Crivera C, Schein JR, Lefebvre P, Peterson ED.

J Manag Care Spec Pharm. 2017 Sep;23(9):980-988. doi: 10.18553/jmcp.2017.23.9.980.

24.

Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States.

Faught E, Laliberté F, Wang Z, Barghout V, Haider B, Lejeune D, Germain G, Choi J, Wagh A, Duh MS.

Epilepsia. 2017 Oct;58(10):1742-1748. doi: 10.1111/epi.13857. Epub 2017 Jul 25.

25.

A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.

Mapel D, Laliberté F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J.

Int J Chron Obstruct Pulmon Dis. 2017 Jun 21;12:1825-1836. doi: 10.2147/COPD.S129007. eCollection 2017.

26.

Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE.

Khorana AA, Berger JS, Wells PS, Seheult R, Ashton V, Laliberté F, Crivera C, Lejeune D, Schein J, Wildgoose P, Lefebvre P, Kaatz S.

Clin Ther. 2017 Jul;39(7):1396-1408. doi: 10.1016/j.clinthera.2017.05.357. Epub 2017 Jun 20.

PMID:
28645879
27.

Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.

Weir MR, Berger JS, Ashton V, Laliberté F, Brown K, Lefebvre P, Schein J.

Curr Med Res Opin. 2017 Oct;33(10):1891-1900. doi: 10.1080/03007995.2017.1339674. Epub 2017 Jul 11.

PMID:
28590785
28.

Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis.

Khorana AA, McCrae KR, Milentijevic D, Fortier J, Nelson WW, Laliberté F, Crivera C, Lefebvre P, Yannicelli D, Schein J.

Res Pract Thromb Haemost. 2017 May 30;1(1):14-22. doi: 10.1002/rth2.12002. eCollection 2017 Jul.

29.

Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban.

Coleman C, Yuan Z, Schein J, Crivera C, Ashton V, Laliberté F, Lefebvre P, Peterson ED.

Curr Med Res Opin. 2017 Jun;33(6):1033-1043. doi: 10.1080/03007995.2017.1297932. Epub 2017 Apr 2.

PMID:
28366075
30.

Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk.

Nelson WW, Laliberté F, Patel AA, Germain G, Pilon D, McCormick N, Lefebvre P.

Curr Med Res Opin. 2017 Apr;33(4):631-638. doi: 10.1080/03007995.2016.1275936. Epub 2017 Jan 24.

PMID:
28008771
31.

Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation.

McHorney CA, Peterson ED, Laliberté F, Germain G, Nelson WW, Crivera C, Schein J, Lefebvre P.

Clin Ther. 2016 Nov;38(11):2477-2488. doi: 10.1016/j.clinthera.2016.09.014. Epub 2016 Oct 24.

PMID:
27789043
32.

Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population.

Law A, Pilon D, Lynen R, Laliberté F, Gozalo L, Lefebvre P, Duh MS.

Reprod Health. 2016 Aug 22;13(1):96. doi: 10.1186/s12978-016-0211-3.

33.

Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.

Deitelzweig S, Laliberté F, Crivera C, Germain G, Bookhart BK, Olson WH, Schein J, Lefebvre P.

Clin Ther. 2016 Aug;38(8):1803-1816.e3. doi: 10.1016/j.clinthera.2016.07.002. Epub 2016 Aug 2.

PMID:
27491278
34.

Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy.

Simon JA, Laliberté F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

Menopause. 2016 Jun;23(6):600-10. doi: 10.1097/GME.0000000000000590.

PMID:
26953655
35.

Change of carrier density at the pseudogap critical point of a cuprate superconductor.

Badoux S, Tabis W, Laliberté F, Grissonnanche G, Vignolle B, Vignolles D, Béard J, Bonn DA, Hardy WN, Liang R, Doiron-Leyraud N, Taillefer L, Proust C.

Nature. 2016 Mar 10;531(7593):210-4. doi: 10.1038/nature16983. Epub 2016 Feb 22.

PMID:
26901870
36.

Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.

LaMori J, Tandon N, Laliberté F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

J Med Econ. 2016;19(4):364-73. doi: 10.3111/13696998.2015.1127252. Epub 2016 Jan 11.

PMID:
26624985
37.

Computerized tomography based tumor-thickness measurement is useful to predict postoperative pathological tumor thickness in oral tongue squamous cell carcinoma.

Madana J, Laliberté F, Morand GB, Yolmo D, Black MJ, Mlynarek AM, Hier MP.

J Otolaryngol Head Neck Surg. 2015 Nov 16;44:49. doi: 10.1186/s40463-015-0089-z.

38.

Clinical parameters predicting development of pulmonary malignancies in patients treated for head and neck squamous cell carcinoma.

Madana J, Morand GB, Alrasheed A, Gabra N, Laliberté F, Barona-Lleó L, Yolmo D, Black MJ, Sultanem K, Hier MP.

Head Neck. 2016 Apr;38 Suppl 1:E1277-80. doi: 10.1002/hed.24210. Epub 2015 Oct 30.

PMID:
26514270
39.

Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users.

Olson WH, Ma YW, Crivera C, Schein J, Lefebvre P, Laliberté F, Dea K, Germain G, Lynch SM.

J Med Econ. 2015;18(12):1074-84. doi: 10.3111/13696998.2015.1076429. Epub 2015 Sep 25.

PMID:
26407193
40.

Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure.

McHorney CA, Crivera C, Laliberté F, Nelson WW, Germain G, Bookhart B, Martin S, Schein J, Lefebvre P, Deitelzweig S.

Curr Med Res Opin. 2015 Dec;31(12):2167-73. doi: 10.1185/03007995.2015.1096242. Epub 2015 Oct 22.

PMID:
26393483
41.

Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin.

Merli GJ, Hollander JE, Lefebvre P, Laliberté F, Raut MK, Germain G, Bookhart B, Pollack CV.

J Med Econ. 2016;19(1):84-90. doi: 10.3111/13696998.2015.1096274. Epub 2015 Oct 27.

PMID:
26390315
42.

Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications.

Crivera C, Nelson WW, Bookhart B, Martin S, Germain G, Laliberté F, Schein J, Lefebvre P.

Curr Med Res Opin. 2015;31(10):1889-95. doi: 10.1185/03007995.2015.1077213. Epub 2015 Sep 4.

PMID:
26211815
43.

Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy.

Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberté F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA.

J Med Econ. 2015;18(12):1041-9. doi: 10.3111/13696998.2015.1074583. Epub 2015 Aug 26.

PMID:
26201251
44.

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users.

Laliberté F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, Vanderpoel J, Germain G, Lefebvre P.

Adv Ther. 2015 Apr;32(4):387. doi: 10.1007/s12325-015-0202-8. No abstract available.

45.

Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban.

Merli GJ, Hollander JE, Lefebvre P, Laliberté F, Raut MK, Olson WH, Pollack CV Jr.

Hosp Pract (1995). 2015;43(2):85-93. doi: 10.1080/21548331.2015.1021659. Epub 2015 Mar 19.

PMID:
25791984
46.

Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.

Laliberté F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, Vanderpoel J, Germain G, Lefebvre P.

Adv Ther. 2015 Mar;32(3):216-27. doi: 10.1007/s12325-015-0189-1. Epub 2015 Mar 18. Erratum in: Adv Ther. 2015 Apr;32(4):387.

47.

Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.

Laliberté F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, Vanderpoel J, Germain G, Lefebvre P.

Clin Ther. 2015 Mar 1;37(3):554-62. doi: 10.1016/j.clinthera.2015.02.001. Epub 2015 Mar 4. Erratum in: Clin Ther. 2015 Aug;37(8):1870-1.

48.

Reply: Essential need for research in hepatitis C.

Tandon N, Balart LA, Laliberté F, Pilon D, Lefebvre P, Germain G, Prabhakar A.

J Med Econ. 2015;18(7):514-5. doi: 10.3111/13696998.2015.1017504. Epub 2015 Apr 24. No abstract available.

PMID:
25744591
49.

Review of the fundamental theories behind small angle X-ray scattering, molecular dynamics simulations, and relevant integrated application.

Boldon L, Laliberte F, Liu L.

Nano Rev. 2015 Feb 25;6:25661. doi: 10.3402/nano.v6.25661. eCollection 2015.

50.

Atmospheric dynamics. Constrained work output of the moist atmospheric heat engine in a warming climate.

Laliberté F, Zika J, Mudryk L, Kushner PJ, Kjellsson J, Döös K.

Science. 2015 Jan 30;347(6221):540-3. doi: 10.1126/science.1257103.

Supplemental Content

Loading ...
Support Center